NCT01616303.

Trial name or title	A controlled study of effectiveness of oregovomab (antibody) plus chemotherapy in advanced ovarian cancer
Methods	Randomised open‐label phase II
Participants	80 women with newly diagnosed ovarian, tubal, or peritoneal cancer after optimal cytoreductive surgery about to start first‐line chemotherapy
Interventions	Carboplatin + paclitaxel vs carboplatin + paclitaxel + oregovomab
Outcomes	Adverse events Immune responses Survival Clinical responses
Starting date	June 2012
Contact information
Notes	Active not recruiting, September 2017